Barely Significant
← all excerpts

Targeting the p53/xCT/GSH Axis with PRIMA-1<sup>Met</sup> Combined with Sulfasalazine Shows Therapeutic Potential in Chronic Lymphocytic Leukemia.

Int J Mol Sci · 2025 · PMC12193190 · PMID 40565026

Europe PMCDOI
1
hedged sentence
—
closest p
—
boldest claim

The sentences

an increasing trendno p-value reported
The depletion of GSH was not associated with a significant increase in ROS in OSU cells after treatment with PRIMA1 Met alone, while it was associated with an increasing trend of ROS in MEC-1 cells ( Figure 8 B).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.